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It is postulated that the unstable hydroxylamine metabolite of sulphamethoxazole is 
responsible for the adverse reactions to co-trimoxazole and in HIV infection systemic 
glutathione deficiency leads to a reduced capacity to counteract the hydroxylamine 
toxicity. This hypothesis has been investigated by studying the metabolism of 
sulphamethoxazole and assessing glutathione status in HIV infection in order to 
explore the modification of treatment. It is concluded that the toxicity of plasma 
sulphamethoxazole hydroxylamine is counteracted by normal glutathione concen­
trations as is the case in HIV-seropositive patients, but that increased oxidation 
within certain cells in HIV infected individuals may possibly give rise to increased 
concentrations of reactive intermediates of sulphamethoxazole.
Sulphametrole and sulphamethoxazole have similar half-lives but are metabolized 
differently: in vivo no oxidised metabolites of sulphametrole could be detected. In a 
retrospective study the rate of adverse reactions to trimethoprim-sulphametrole 
appeared to be in the lower range of those reported for trimethoprim-sulphamethox- 
azole indicating that the combination of trimethoprim-sulphametrole may be more 
favourable. The ratio of trimethoprim :sulphonamide is 1:5, but in-vitro studies with 
Toxoplasma gondii indicate that because of the synergic effect of both agents the dose 
of sulphonamide is possibly unnecessarily high.
Introduction
The combination of trimethoprim and sulphamethoxazole (co-trimoxazole) is an 
important drug for the treatment and primary and secondary prophylaxis of 
Pneumocystis carinii pneumonia (PCP) in patients with infection caused by the human 
immunodeficiency virus (HIV). However, the administration of co-trimoxazole in these 
patients is often hampered because the frequency of adverse reactions to this drug in 
H IV  infected patients is much higher compared with seronegative individuals (Kovacs 
et a l 1984). These side-effects, which are often labeled as ‘allergic’, consist of rash, fever 
and damage to liver parenchymal cells. Although H IV  seropositive individuals are more 
susceptible to side-effects similar to those associated with a number of other, unrelated 
drugs (reviewed by Coopman et a l., 1993; Koopmans et a l., 1995), this review focuses 
on the side-effects of co-trimoxazole.
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Some years ago, we hypothesized that this increased frequency of toxicity 
to co-trimoxazole is caused by a combination of two factors (van der Ven et a l., 
1991, 19946). First of all, the hydroxylamine derivative of sulphamethoxazole is 
an unstable metabolite that can undergo auto-oxidation to become a protein-reactive 
nitroso derivative, and this substance could be responsible for the adverse reactions 
to co-trimoxazole (Shear et a l., 1986; Rieder et a l., 1988, 1989). This means that 
the sulphonamide component of co-trimoxazole is largely responsible for the 
side-effects, although the oxidation of trimethoprim could possibly also lead to 
hydroxylamine formation. Secondly, H IV  infected individuals have a systemic 
glutathione deficiency (Buhl et a l., 1989; Eck et a l., 1989). This deficiency implies that 
there is a reduced capacity to prevent auto-oxidation of the unstable sulphonamide 
intermediates, and to scavenge reactive compounds. As a consequence, there is an 
increased exposure of cells to toxic intermediates and this could lead to the adverse 
reactions.
The hypothesis was the subject of a series of investigations carried out by our group. 
The investigations comprised studies of the metabolism of sulphamethoxazole and other 
sulphonamides, the assessment of the glutathione status in HIV-infected patients and 
the exploration of treatment modifications.
Sulphamethoxazole metabolism
Sulphamethoxazole is extensively metabolized in vivo; its metabolic pathways involve 
acetylation, oxidation and glucuronidation (Vree & Mekster, 1987; Vree et a l., 1994). 
Oxidation takes place at different positions of the molecule: the unstable, reactive 
hydroxylamine metabolite is formed by oxidation of the N4 nitrogen atom while 
oxidation of the C5 methyl group leads to the stable 5-hydroxy metabolite. Formation 
of both metabolites by cytochrome P450-mediated reaction was demonstrated in vitro 
using human liver microsomes. In vitro more sulphamethoxazole was N-hydroxylated 
than 5-hydroxylated (van der Ven et a l 1995a).
The pharmacokinetics of sulphamethoxazole and its metabolites were reported 
in healthy volunteers after a single dose (Vree et a l., 1994, 1995). The patterns of 
the formation and elimination of sulphamethoxazole hydroxylamine were similar to 
the other metabolic products, and the renal excretion of sulphamethoxazole 
hydroxylamine accounted for 2-4% of the recovered dose (van der Ven et a l., 
1994c). The mean residence time of the hydroxylamine metabolite was 5-5 h; the 
renal clearance amounted 4-39 L/h. Thus, under physiological conditions most 
sulphamethoxazole hydroxylamine seems to be stable, escapes the liver and is excreted 
by the kidney.
Next, the pharmacokinetics of sulphamethoxazole and its metabolites were also 
investigated in HIV-seropositive individuals after a single oral dose (van der Ven et a l., 
19956). Sulphamethoxazole hydroxylamine is the only compound for which the urinary 
recovery was found to be different from healthy volunteers. The impaired recovery of 
sulphamethoxazole hydroxylamine in HIV-seropostive patients (50% reduction) may be 
explained by secondary metabolism to the protein reactive nitroso derivatives. At the 
time of the investigations, it was not clear whether this auto-oxidation occurred in the 
urine ex vivo or in vivo because of glutathione deficiency. Because the urinary excretion 
of all other metabolites of sulphamethoxazole, including 5-hydroxy sulphamethoxazole 
and N4-acetyl-5-hydroxy-sulphamethoxazole, was similar between HIV-seropositive
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individuals and healthy controls, we concluded that there was no difference in oxidation, 
acetylation and glucuronidation (van der Ven et a l., 19946). Taken together, we 
conclude that sulphamethoxazole hydroxylamine is indeed being formed during 
treatment with sulphamethoxazole by both normal individuals and HIV-seropositive 
patients.
Although the cytotoxic potential of hydroxylamines of sulphonamides can be 
demonstrated in vitro (Rieder et a l., 1988, 1989), the relative toxicity of these 
compounds, as compared with the parent compounds (which also exert cytotoxicity; A. 
J. A. M. van der Ven, unpublished observations), has not been assessed in terms of the 
relative concentrations in vivo.
Glutathione status
Glutathione is the main intracellular defense against oxidative stress and is of major 
importance for xenobiotic metabolism. Intracellular concentrations of glutathione are 
high, while plasma concentrations are low. Several groups have reported decreased 
glutathione concentrations in H IV  infection, in particular in plasma, broncho-alveolar 
lavage, peripheral blood mononuclear cells (Buhl et a l., 1989; Eck et a l., 1989), and 
also in CD4+  and C D 8 + T lymphocytes (Roederer et a l., 1991). Based on these 
investigations, it was concluded that H IV  infection is associated with a systemic 
glutathione deficiency. Glutathione concentrations in CD4+  and C D 8 + T 
lymphocytes were determined using monochlorobimane as a fluorescent label. However, 
when we evaluated this method, we found that many variables influenced the cellular 
fluorescence, including the presence of alternative metabolic pathways for 
monochlorobimane and the rapid excretion of glutathione-bimane conjugate out of the 
cell. We concluded that this label cannot be used to assess glutathione levels in these 
cells (van der Ven et a l., 1994<r/).
High performance liquid chromatography is a validated method to measure 
glutathione concentrations and was employed to measure free and protein-bound 
glutathione concentrations in HIV-seropositive individuals and healthy controls. Both 
forms of glutathione were determined because free glutathione is important for the 
maintenance of thiol redox status, while increased concentrations of protein-bound 
glutathione indicate oxidative stress. We found that free intracellular glutathione 
concentrations in erythrocytes, C D  14 cells and CD4 cells were not different between 
HIV-seropositive individuals and healthy controls (A. J. A. M . van der Ven, H. Blom, 
W. H. M . Peters. L. E. H. Jacobs, I. J. O. Verver, P. P. Koopmans, P. Demacker & 
J. W. M . van der Meer, unpublished observations). In addition, we found that plasma 
concentrations of free glutathione were also not different. Based on these findings, we 
concluded that H IV  infection is not associated with a systemic glutathione deficiency. 
It was found, however, that the protein-bound form of glutathione was increased, 
particularly in CD4 cells of H IV  seropositive subjects which strongly suggests the 
presence of increased oxidative stress.
So far, we have concluded that the toxicity of sulphamethoxazole hydroxylamine in 
plasma is counteracted by normal glutathione concentrations, not only in normal 
controls but also in HIV-seropositive patients. It could be speculated that in these 
patients, the presence of increased oxidation within certain cells may lead to increased 
concentrations of reactive intermediates of sulphamethoxazole. It is clear that further 
research is needed in this area.
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Treatment modification
Treatment modification with regard to the choice of the sulphonamides was also 
investigated. We explored the metabolism of a number of different sulphonamides to 
try and select a sulphonamide that would generate less hydroxylamine. Ten different 
sulphonamides were incubated in vitro with human liver microsomes. These experiments 
indicated that all sulphonamides tested generated stable as well as unstable oxidised 
metabolites, but not all to the same extent. The generation of oxidised products was 
least for sulphametrole. In vivo the rate of oxidation between the various sulphonamides 
also differs; the same holds true for the rate of acetylation and glucuronidation (Vree 
& Hekster, 1987). It is generally accepted that the acetylated compound is non-toxic 
(Rieder et al., 1991); thus, a sulphonamide that is accessible for acetylation but not for 
oxidation may be more favourable than an extensively metabolized compound like 
sulphamethoxazole. The acetylation of sulphametrole in vivo has been previously 
reported (Hekster et al., 1981), and to date is the only metabolic reaction. 
Re-examination of sulphametrole metabolism using mass spectrometry did not indicate 
the presence of any oxidised metabolite in the urine of healthy controls and H IV  
seropositives (W. Welz, personal communication). Since a stable hydroxy metabolite 
could not be detected, it is likely that sulphametrole is not accessible for cytochrome 
P450 mediated reactions in vivo. Like sulphamethoxazole, sulphametrole is 
commercially available in a 5:1 dose ratio with trimethoprim (Co-soltrim). 
Sulphamethoxazole and sulphametrole have similar half-lifes (10 h).
From the inability to detect hydroxylamine metabolites of sulphametrole, we were 
eager to know whether administration of sulphametrole would meet with fewer adverse 
effects, especially in H IV  seropositive patients. This was supported by a report in the 
literature, in which sulphametrole did not appear to be associated with haemolysis when 
administered in a population with a high prevalence of glucose-6-phosphate 
dehydrogenase deficiency (Plummer et al., 1983). These patients lack the capacity to 
keep glutathione in its reduced form, especially in the red blood cells; 
sulphamethoxazole is known to cause haemolysis in these patients (Beutler, 1991). 
Recently, we performed a retrospective analysis of 58 H IV  infected patients treated for 
PCP with Co-soltrim in two centres. The analysis showed that only skin reactions or 
fever were indications to alter medication and that adverse reactions occurred less 
frequently than has been reported previously for co-trimoxazole (A. J. A. M. van der 
Ven, A. Rieger, A. Brahten, R. Reiman, T. B. Vree, P. P. Koopmans, J. W. M. van 
der Meer, personal observations). These results would justify a prospective controlled 
study comparing the frequency of side-effects of sulphamethoxazole and sulphametrole 
in HIV-infected patients.
Since our hypothesis points to a concentration-dependent mechanism rather than to 
an allergic (i.e., concentration-independent) mechanism, dose reduction would be an 
option. Such a strategy finds some support from the study of Schneider et al. (1992), 
which demonstrated that a relatively low dosage of co-trimoxazole (480 mg daily) for 
PCP prophylaxis in HIV-positive patients was associated with delayed occurrence of 
side-effects than a higher dosage (960 mg daily). In view of this dosage dependency, we 
investigated the optimal dosage ratio of sulphonamide and dihydrofolate reductase 
(D H FR ) inhibitors (trimethoprim and pyrimethamine). At present the achieved plasma 
concentration of the sulphamethoxazole (100-200 mg/L) is much higher than that of 
the D H F R  inhibitor (for trimethoprim 5-10 g/L). The dosage recommendations are
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based on inhibitory concentrations of each compound separately without taking into 
account the synergic effect of the combination. This synergic effect was demonstrated 
in an in-vitro study using Toxoplasma gondii. We found that the 50% inhibitory 
concentration of sulphamethoxazole reduced from 500 to 0.05 g/L when pyrimethamine
0.05 g/L was added to the medium; the plasma concentrations of pyrimethamine 
obtained with a once weekly dose of 75 mg are around 0.2 g/L (A. J. M . van der Ven, 
E. M . E. Schoondermark van de Ven, W . Camps, W. J. G. Melchers, P. P. Koopmans, 
J. W. M . van der Meer & J. M . D. Galama, personal observations). These findings could 
imply that the present dosage recommendations for sulphonamides, when combined 
with trimethoprim or pyrimethamine, are too high, and thereby result in unnecessary 
increased toxicity. Reduction of the toxicity of the current first line treatments for 
P. carinii and T. gondii by selection of a less toxic sulphonamide used with a D H F R  
inhibitor at an adjusted dosage ratio should be investigated.
References
Beutler, E. (1991). Glucose-6-phosphate dehydrogenase deficiency. New England Journal of 
Medicine 321, 169-74.
Buhl, R., Jaffe, H. A., Holroyd, K. J., Wells, F. B., Mastrangeli, A., Saltini, C. et al. (1989). 
Systemic glutathione deficiency in symptom-free HIV seropositive individuals. Lancet ii, 
1294—8.
Coopman, S. A., Johnson, R. A., Platt, R. & Stern, R. S. (1993). Cutaneous disease and drug 
reactions in HIV infection. New England Journal of Medicine 328, 1670-4.
Eck, H. P., Gmünder, H., Hartmann, T., Petzoldt, D., Daniel, V. & Dröge, W. (1989). Low 
concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected patients. 
Biological Chemistry Hoppe-Seyler 370, 101-8.
Hekster, Y. A., Vree, T. B., Damsma, J. E. & Friesen, W. T. (1981). Pharmacokinetics of 
sulphametrole and its metabolite N4-acetylsulphametrole in man. Journal of Antimicrobial 
Chemotherapy 8, 133-44.
Koopmans, P. P., van der Ven, A. J. A. M., Vree, T. B. & van der Meer, J. W. M. (1995). 
Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic 
or toxic? AIDS 9, 217-22.
Kovacs, J. A., Hiemenz, J. W., Macher, A. M., Stover, D., Murray, H. W., Sclhamer, J. et al. 
(1984). Pneumocystis carinii pneumonia: a comparison between patients with the acquired 
immunodeficiency syndrome and patients with other immunodeficiencies. Annals of Internal 
Medicine 100, 663-71.
Plummer, F. A., Nsanze, H., D ’Costa, L. J., Karasira, P., Maclean, I. W., Ellison, R. H. et al. 
(1983). Single-dose therapy of chancroid with trimethoprim-sulphametrole. New England 
Journal of Medicine 309, 67-71.
Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K. & Spielberg, S. P. (1991). Prominence of 
slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. 
Clinical Pharmacology and Therapeutics 49, 13-7.
Rieder, M. J., Uetrecht, J., Shear, N. H., Cannon, M., Miller, M. & Sielberg, S. P. (1989). 
Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with 
hydroxyl-amine metabolites. Annals of Internal Medicine 110, 286-9.
Rieder, M. J., Uetrecht, J., Shear, N. H. & Spielberg, S. P. (1988). Synthesis and in vitro toxicity 
of hydroxylamine metabolites of sulfonamides. Journal of Pharmacology and Experimental 
Therapeutics 244, 724-8.
Roederer, M., Staal, F. J., Osada, H. & Herzenberg, L. A. (1991). CD4 and CD8 T cells with 
high intracellular glutathione levels are selectively lost as HIV infection progresses. 
International Immunology 3, 933-7.
60 A. J. A. M. van der Yen et al
Schneider, M. M. E., Hoepelman, A. I. M., Eeftinck-Schattenkerk, J. K. M., Nielsen, T. L., van 
der Graaf, Y., Frissen, J. P. H. J. et al. (1992). A controlled trial of aerosolized pentamidine 
or trimethoprim-siilphamethoxazole as primary prophylaxis against Pneumocystis carinii 
pneumonia in patients with human immunodeficiency virus infection. New England Journal 
of Medicine 327, 1836-41.
Shear, N. H., Spielberg, S. P., Grant, D. M., Tang, B. K. & Kalow, W. (1986). Differences 
in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Annals of Internal 
Medicine 105, 179-84.
van der Ven, A. J. A. M., Koopmans, P. P., Vree, T. B. & van der Meer, J. W. M. (1994«). Drug 
intolerance in HIV disease. Journal of Antimicrobial Chemotherapy 34, 1-5. 
van der Ven, A. J. A. M., Koopmans, P. P., Vree, T. B. & van der Meer, J. W. M. (1991). Adverse 
reactions to co-trimoxazole in HIV infection. Lancet 338, 431-3. 
van der Ven, A. J. A. M., Mantel, M. A., Vree, T. B., Koopmans, P. P. & van der Meer, J. W. 
M. (19946). Formation and elimination of sulphamethoxazole hydroxylamine after oral 
administration of sulphamethoxazole. British Journal of Clinical Pharmacology 38, 147-50. 
van der Ven, A. J. A. M., Mier, P., Peters, W. H. M., Dolstra, H., van Erp, P. E. J., Koopmans, 
P. P. & van der Meer, J. W. M. (1994c). Monochlorobimane does not selectively label 
glutathione in peripheral blood mononuclear cells. Analytical Biochemistry 217, 41-7. 
van der Ven, A. J. A. M., Peters, W. H. M., Vree, T. B., Koopmans, P. P. and van der Meer, 
J. W. M. (1995«). Oxidation of sulfamethoxazole by human liver microsomes. In press, 
van der Ven, A. J. A. M., Vree, T. B., Koopmans, P. P. & van der Meer, J. W. M. (19956). 
Urinary recovery and kinetics of sulfamethoxazole and its metabolites in HIV seropositive 
patients and healthy volunteers after a single oral dose of sulfamethoxazole. British Journal 
of Clinical Pharmacology 39, 621-5.
Vree, T. B. & Hekster, Y. A. (1987). Clinical pharmacokinetics of sulfonamides and their 
metabolites. In An Encyclopedia of Antibiotics and Chemotherapy, Vol. 37, pp. 1-214. S. 
Karger, Basle.
Vree, T. B., van der Ven, A. J. A. M., Koopmans, P. P., van Ewijk-Beneken Kolmer, E. W. J.
& Verwey-van Wissen, C. P. W. G. V. (1995). Pharmokinetics of sulamethoxazole with its 
hydroxy metabolites and N-4-acetyl-glucuronide, Nl-glucuronide conjugates in healthy 
volunteers. Clinical Drug Investigation 9, 43-53.
Vree, T. B., van der Ven, A. J. A. M., Verwey-van Wissen, C. P. W. G. M., van Ewijk-Beneken 
Kolmer, E. W. J., Swolfs, A. E. M., van Galen, P. M. et al. (1994). Isolation, identification 
and determination of sulfamethoxazole and its known metabolites in human plasma and 
urine by high-performance liquid chromatography. Journal of Chromatography 658, 327-40.
